BeiGene Pipeline Portfolio

Three late-stage, and 12 early-stage clinical assets (not including compounds from Amgen collaboration)

Global
China

As of 3/2/2020

	ASSETS	PROGRAMS	DOSE ESC. PH1a	DOSE EXPANSION PH1b	DOSE EXPANSION PH2*	PIVOTAL PH2**	PIVOTAL PH3	FILED	MARKET	COMMERCIAL RIGHTS	PARTNER
Internally Developed	**zanubrutinib** *(BTK)*	**monotherapy**	*R/R MCL (Accelerated approval in the U.S. Nov. 14, 2019)*							*Global*	
			R/R MCL, R/R CLL/SLL (NDAs accepted by NMPA)								
			R/R WM								
			WM, 1L CLL/SLL, R/R CLL/SLL								
			R/R MZL								
			Previously treated CLL/SLL (ibrutinib intolerant)								
		combination	*+rituximab 1L MCL*								
			+obinutuzumab R/R FL								
	tislelizumab *(PD-1)*	**monotherapy**	*R/R cHL (approved December 26, 2019)*							*Global*	
			2L+ UC (NDA accepted by NMPA)								
			2L NSCLC, 1L HCC, 2L ESCC								
			2L/3L HCC								
			R/R NK/T-cell lymphoma								
		+ chemo	*1L Sq. NSCLC, 1L Non-Sq. NSCLC, 1L NPC, 1L SCLC*								
			1L GC, 1L ESCC								
		+ pamiparib *(PARP)*	*Solid tumors*								
		+ zanubrutinib *(BTK)*	*B-cell malignancies*								
	pamiparib *(PARP)*	**monotherapy**	*1L platinum-sensitive GC maintenance*							*Global*	
			2L platinum-sensitive OC maintenance								
			3L gBRCA+ OC								
			Solid tumors								
		+ TMZ *(chemo)*	*Solid tumors*								
		+ RT/TMZ *(RT/chemo)*	*Glioblastoma*								
	lifirafenib *(RAF Dimer)*	**monotherapy**	*B-Raf- or K-RAS/N-RAS-mutated solid tumors*							*Global*	
			B-Raf- or K-RAS/N-RAS-mutated solid tumors								
	BGB-A333 *(PD-L1)*	**monotherapy & + tislelizumab**	*Solid tumors*							*Global*	
	BGB-A425 *(TIM-3)*	**monotherapy & + tislelizumab**	*Solid tumors*							*Global*	
	BGB-A1217 *(TIGIT)*	**+ tislelizumab**	*Solid tumors*							*Global*	
	BGB-A445 *(OX40)*	**+ tislelizumab**	*Solid tumors*							*Global*	
	BGB-11417 *(Bcl-2)*	**monotherapy & + zanubrutinib**	*Phase 1 study startup ongoing*							*Global*	
Collaborations	**Sitravatinib**	*(multi-kinase inhibitor)*	*NSCLC, RCC, OC, MEL, HCC/GEJ*							*Asia ex-Japan, AU, NZ*	Mirati
	ZW25	*(bispecific HER2 antibody)*	*Planned (in Ph2 ex-China by Zymeworks)*							*Asia ex-Japan, AU, NZ*	Zymeworks
	ZW49	*(bispecific anti-HER2 ADC)*	*Planned (in Ph1 ex-China by Zymeworks)*							*Asia ex-Japan, AU, NZ*	Zymeworks
	BGB-3245	*(B-RAF)*	*Solid tumors*							*Asia ex-Japan*	SpringWorks[1]
	SEA-CD70	*(anti-CD70)*	*Planned (starting Ph.1 ex-Asia by Seattle Genetics)*							*Asia ex-Japan, AU, NZ*	Seattle Genetics
	DKN-01	**+ tislelizumab**	*Trials in GC/GEJ planned*							*Asia ex-Japan, AU,NZ*	Leap Therapeutics

*Some indications will not require a non-pivotal Ph2 clinical trial prior to beginning pivotal Ph2 or Ph3 clinical trials. **Confirmatory clinical trials post approval are required for accelerated approvals. 1.By MapKure, a JV with SpringWorks